The Form 4 filing for Terilyn J. Monroe was filed on November 19, 2026. The five sales took place one day earlier, on November 18, 2026. Form 4 is an SEC report that records changes in a company insider's stock ownership.
Guardant Health is listed in the healthcare sector, in the diagnostics and research industry.
Transaction details
| Transaction | |
|---|---|
| Date of Earliest Transaction | 2026-11-18 |
| Date of Latest Transaction | 2026-11-18 |
| Buy/Sell | sell |
| Transaction Count | 5 |
| Shares Transacted | 3,842 |
| Price | $142.41 |
| Total Transaction Value | $547,149.36 |
| Insider | |
| Ticker Symbol | GH |
| Company | Guardant Health, Inc. |
| Insider Name | Monroe Terilyn J. |
| Insider Title | Chief People Officer |
| Sector - Industry | Healthcare - Diagnostics & Research |
| Holdings | |
| Total Shares Owned After Transaction | 21,058 |
| Position Size Change | 15.43% |
| Filing | |
| Filing Date | 2026-11-19 |
| SEC Link | View filing |
FAQ
What type of transaction is this?
These were sales of Guardant Health (GH) shares, reported with transaction code S. The filing lists five sale transactions by Terilyn J. Monroe, the company's chief people officer.
What was the average price of the transaction?
The average sale price across the five transactions was $142.41 per share, rounded to the nearest cent.
How did this transaction affect the insider's holdings?
The sales reduced the reported holdings by 3,842 shares, leaving 21,058 shares owned afterward. The shares sold were 15.43% of the 24,900 shares held before the sales.
What's the total transaction value?
The five transactions had a total value of $547,149.36, rounded to cents. The unrounded reported value was $547,149.3582.
Are there any special circumstances around this transaction?
The filing information identifies a Rule 10b5-1 trading-plan reference. This type of plan sets trading instructions ahead of time. The available details do not show whether that reference applies to all five sales or only some. Footnote text is not available to confirm the plan's scope, adoption date, or trading schedule.
For research purposes only; not investment advice.